Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss

Stock Information for Otonomy Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Otonomy Inc.

Otonomy Announces Change in Stock Exchange Listing
Otonomy Provides Corporate Update
Otonomy Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus
Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update
Otonomy to Participate in the H.C. Wainwright Global Investment Conference
Otonomy Announces OTO-825 Presentation at the American Society of Gene & Cell Therapy Annual Meeting

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.